Aytu Biopharma (AYTU) Cash from Operations (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Cash from Operations data on file, last reported at 4182000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 35.21% year-over-year to 4182000.0 in Q1 2026; TTM through Mar 2026 was 1678000.0, a 130.35% increase from a year earlier, with the FY2025 full-year figure at 1937000.0, down 39.55% from the prior year.
• Cash from Operations for Q1 2026 stood at 4182000.0, down from 3675000.0 in the prior quarter.
• Over the last five years, Cash from Operations for AYTU reached as high as 9371000.0 in Q2 2023 and fell as low as 9115000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 1517000.0 across 5 years, with a median of 788000.0 in 2024.
• Across the five-year window, Cash from Operations soared 2251.85% in 2024 and sank 2441.34% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 2488000.0 in 2022, then jumped by 94.57% to 135000.0 in 2023, then surged by 2251.85% to 2905000.0 in 2024, then gained by 26.51% to 3675000.0 in 2025, then sank by 213.8% to 4182000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 4182000.0 in Q1 2026, 3675000.0 in Q4 2025, and 618000.0 in Q3 2025.